NH TherAguix Announces Publication of Groundbreaking Study on AGuIX® Nanoparticles Enhancing Cervical Cancer Treatment
03 juil. 2024 08h30 HE
|
NH TherAguix SA
PRESS RELEASE NH TherAguix Announces Publication of Groundbreaking Study on AGuIX® Nanoparticles Enhancing Cervical Cancer Treatment Key clinical milestone showcasing the potential of AGuIX®, a...
NH TherAguix Announces the completion of Phase I Recruitment for the Pancreas Cohort and the entry into Phase II in the NANOSMART phase Ib/II trial.
01 juil. 2024 08h30 HE
|
NH TherAguix SA
PRESS RELEASE NH TherAguix Announces the completion of Phase I Recruitment for the Pancreas Cohort and the entry into Phase IIin the NANOSMART phase Ib/II trial. Key clinical milestone...
Publication of an article in Nature's Scientific Reports describing the quantification of novel radio-enhancer AGuIX® developed in brain metastases
10 juin 2024 08h32 HE
|
NH TherAguix SA
PRESS RELEASE Nature's Scientific Reports publishes an article describing the quantification of novel radio-enhancer AGuIX® developed in brain metastases Confirmation, consistently with already...
NH TherAguix receives FDA Fast Track designation
30 mai 2024 08h30 HE
|
NH TherAguix SA
PRESS RELEASE NH TherAguix receives FDA Fast Track designation for AGuIX®, its novel radio-enhancer in the treatment of malignant gliomas, and provides an update on its developments and prospects ...
NH TherAguix appoints Jean-Philippe DEL as Chief Financial Officier
15 janv. 2024 05h10 HE
|
NH TherAguix SA
PRESS RELEASE NH TherAguix appoints Jean-Philippe Del as Chief Financial Officer. Paris, January 15th, 2024 – NH TherAguix SA (“NHT”), a Phase II clinical stage biotech company...
Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis
30 nov. 2023 12h23 HE
|
NH TherAguix SA
Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis Recruitment led by...